AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions
暂无分享,去创建一个
Thomas J. Smith | Christine Miaskowski | B. Schmidt | J. Farrar | M. Bennett | P. Mantyh | P. Dougherty | J. Paice | C. Miaskowski | Judith A. Paice | Matt Mulvey | Michael Bennett | Patrick M. Dougherty | John T. Farrar | Patrick W. Mantyh | Brian Schmidt | M. Mulvey
[1] Jason D. Wright,et al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Ohrbach,et al. Approaches to Demonstrating the Reliability and Validity of Core Diagnostic Criteria for Chronic Pain. , 2016, The journal of pain : official journal of the American Pain Society.
[3] R. Dworkin,et al. Multidimensional Diagnostic Criteria for Chronic Pain: Introduction to the ACTTION-American Pain Society Pain Taxonomy (AAPT). , 2016, The journal of pain : official journal of the American Pain Society.
[4] R. Dworkin,et al. The Role of Psychosocial Processes in the Development and Maintenance of Chronic Pain. , 2016, The journal of pain : official journal of the American Pain Society.
[5] R. Ohrbach,et al. Assessment of Psychosocial and Functional Impact of Chronic Pain. , 2016, The journal of pain : official journal of the American Pain Society.
[6] David A. Williams,et al. Overlapping Chronic Pain Conditions: Implications for Diagnosis and Classification. , 2016, The journal of pain : official journal of the American Pain Society.
[7] T. Jensen,et al. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel , 2016, Pain.
[8] A. Benson,et al. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. , 2016, Clinical colorectal cancer.
[9] A. Saykin,et al. Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Jonathan G. Lees,et al. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy , 2016, Pain.
[11] H. Friess,et al. Neural plasticity in pancreatitis and pancreatic cancer , 2015, Nature Reviews Gastroenterology &Hepatology.
[12] Ryan M. Cassidy,et al. MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy , 2015, Brain, Behavior, and Immunity.
[13] S. Flatters,et al. Pharmacological Modulation of the Mitochondrial Electron Transport Chain in Paclitaxel-Induced Painful Peripheral Neuropathy , 2015, The journal of pain : official journal of the American Pain Society.
[14] Ryan M. Cassidy,et al. The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4 , 2015, The Journal of Neuroscience.
[15] P. Meltzer,et al. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] T. Vanderah,et al. Use of Animal Models in Understanding Cancer-induced Bone Pain , 2015, Cancer growth and metastasis.
[17] C. Loprinzi,et al. Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. , 2015, Journal of pain and symptom management.
[18] S. C. Adams,et al. Impact of cancer and chemotherapy on autonomic nervous system function and cardiovascular reactivity in young adults with cancer: a case-controlled feasibility study , 2015, BMC Cancer.
[19] B. Schmidt,et al. TMPRSS2, a novel membrane-anchored mediator in cancer pain , 2015, Pain.
[20] B. Schmidt. What pain tells us about cancer. , 2015, Pain.
[21] Blair H. Smith,et al. A classification of chronic pain for ICD-11 , 2015, Pain.
[22] D. McLeod,et al. PTHrP-mediated hypercalcemia: causes and survival in 138 patients. , 2015, The Journal of clinical endocrinology and metabolism.
[23] P. Mantyh,et al. NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use. , 2014, Cancer research.
[24] P. Mantyh,et al. Exuberant sprouting of sensory and sympathetic nerve fibers in nonhealed bone fractures and the generation and maintenance of chronic skeletal pain , 2014, PAIN®.
[25] Gillian L. Currie,et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis , 2014, PAIN®.
[26] C. Cleeland,et al. A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. , 2014, Cancer research.
[27] H. Sørensen,et al. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. , 2014, Lung cancer.
[28] S. Shete,et al. Survival patterns in squamous cell carcinoma of the head and neck: pain as an independent prognostic factor for survival. , 2014, The journal of pain : official journal of the American Pain Society.
[29] T. Taverner. Neuropathic pain in people with cancer (part 1): incidence, manifestation, and assessment. , 2014, International journal of palliative nursing.
[30] W. Boogerd,et al. Chemotherapy-induced neuropathy: A comprehensive survey. , 2014, Cancer treatment reviews.
[31] Kathryn A. Lee,et al. Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy , 2014, Cancer.
[32] A. Zedan,et al. Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires. , 2014, Basic & clinical pharmacology & toxicology.
[33] Saranya Chumsri,et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience , 2014, SpringerPlus.
[34] Dawn L Hershman,et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Mantyh. Bone cancer pain: from mechanism to therapy , 2014, Current opinion in supportive and palliative care.
[36] A. Dickenson,et al. Pain and nociception: mechanisms of cancer-induced bone pain. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] A. Miah,et al. Nonsurgical oncological management of cancer pain , 2014, Current opinion in supportive and palliative care.
[38] Y. T. Cheung,et al. Management options for established chemotherapy-induced peripheral neuropathy , 2014, Supportive Care in Cancer.
[39] L. Wu,et al. The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. , 2014, Current oncology.
[40] R. Massey,et al. Brief review: Chemotherapy-induced painful peripheral neuropathy (CIPPN): current status and future directions , 2014, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.
[41] Roman Rolke,et al. Confirming neuropathic pain in cancer patients: Applying the NeuPSIG grading system in clinical practice and clinical research , 2014, PAIN®.
[42] B. Schmidt. The Neurobiology of Cancer Pain , 2014, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[43] R. Baron,et al. Is an easy and reliable diagnosis of localized neuropathic pain (LNP) possible in general practice? Development of a screening tool based on IASP criteria , 2014, Current medical research and opinion.
[44] Thomas J. Smith,et al. The ACTTION-American Pain Society Pain Taxonomy (AAPT): an evidence-based and multidimensional approach to classifying chronic pain conditions. , 2014, The journal of pain : official journal of the American Pain Society.
[45] N. Zhang,et al. Spinal Changes of a Newly Isolated Neuropeptide Endomorphin-2 Concomitant with Vincristine-Induced Allodynia , 2014, PloS one.
[46] R. Freeman,et al. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs , 2014, PAIN®.
[47] Y. Ishida,et al. Characterization of Acute and Chronic Neuropathies Induced by Oxaliplatin in Mice and Differential Effects of a Novel Mitochondria-targeted Antioxidant on the Neuropathies , 2014, Anesthesiology.
[48] M. Bennett,et al. Practical Management of Complex Cancer Pain , 2014 .
[49] Maree T. Smith,et al. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN) , 2013, Front. Pharmacol..
[50] R. Umbas,et al. Anxiety level of early- and late-stage prostate cancer patients , 2013, Prostate international.
[51] P. Mantyh. Bone cancer pain: Causes, consequences, and therapeutic opportunities , 2013, PAIN®.
[52] R. Treede,et al. Pain in chemotherapy-induced neuropathy – More than neuropathic? , 2013, PAIN®.
[53] J. Snowden,et al. Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. , 2013, Journal of pain and symptom management.
[54] M. Koltzenburg,et al. Chemotherapy‐induced peripheral neurotoxicity: A critical analysis , 2013, CA: a cancer journal for clinicians.
[55] A. Pokryszko-Dragan,et al. Bortezomib-induced painful neuropathy in patients with multiple myeloma , 2013, Contemporary oncology.
[56] Ripamonti Carla,et al. Prevention and Treatment of Bone Metastases in Breast Cancer , 2013, Journal of clinical medicine.
[57] C. Farrell. Bone metastases: assessment, management and treatment options. , 2013, British journal of nursing.
[58] L. Carey,et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] Kecheng Xu,et al. Alleviating visceral cancer pain in patients with pancreatic cancer using cryoablation and celiac plexus block. , 2013, Cryobiology.
[60] C. Cleeland,et al. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy , 2013, Cancer Chemotherapy and Pharmacology.
[61] P. Dougherty,et al. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine , 2013, Cancer Chemotherapy and Pharmacology.
[62] Liying Zhang,et al. Minimal clinically important differences in the brief pain inventory in patients with bone metastases , 2013, Supportive Care in Cancer.
[63] G. Altavilla,et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[64] D. Pud,et al. Chemotherapy‐Induced Neuropathic Pain and Its Relation to Cluster Symptoms in Breast Cancer Patients Treated with Paclitaxel , 2013, Pain practice : the official journal of World Institute of Pain.
[65] H. Kehlet,et al. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide , 2012, Acta oncologica.
[66] Dong-Wan Kim,et al. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. , 2012, Lung cancer.
[67] C. Cleeland,et al. Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty. , 2012, The journal of pain : official journal of the American Pain Society.
[68] Bond-Smith Giles,et al. Only women with symptoms need to have their breast implants removed, says government , 2012 .
[69] M. Stubblefield,et al. A prospective surveillance model for physical rehabilitation of women with breast cancer , 2012, Cancer.
[70] C. Cleeland,et al. Subclinical Peripheral Neuropathy Is a Common Finding in Colorectal Cancer Patients Prior to Chemotherapy , 2012, Clinical Cancer Research.
[71] C. V. D. van de Velde,et al. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. , 2012, The Lancet. Oncology.
[72] Guido Cavaletti,et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. , 2012, Critical reviews in oncology/hematology.
[73] S. Buga,et al. The management of pain in metastatic bone disease. , 2012, Cancer control : journal of the Moffitt Cancer Center.
[74] Liying Zhang,et al. Symptom clusters in patients with bone metastases—a reanalysis comparing different statistical methods , 2012, Supportive Care in Cancer.
[75] M. Koltzenburg,et al. Normal pressure hydrocephalus: how often does the diagnosis hold water? , 2012, Neurology.
[76] B. Laird,et al. Quantitative Sensory Testing to assess the sensory characteristics of cancer‐induced bone pain after radiotherapy and potential clinical biomarkers of response , 2012, European journal of pain.
[77] G. Cavaletti,et al. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. , 2011, The Lancet. Oncology.
[78] M. Rodionova,et al. Clinical symptoms of bone marrow metastases in breast cancer patients , 2011 .
[79] G. Hostetter,et al. Perineural invasion and associated pain in pancreatic cancer , 2011, Nature Reviews Cancer.
[80] P. Dougherty,et al. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. , 2011, The journal of pain : official journal of the American Pain Society.
[81] Gordon D. Murray,et al. Characterization of cancer-induced bone pain: an exploratory study , 2011, Supportive Care in Cancer.
[82] Yelena Granovsky,et al. Pronociceptive pain modulation in patients with painful chemotherapy-induced polyneuropathy. , 2011, Journal of pain and symptom management.
[83] R. Portenoy. Treatment of cancer pain , 2011, The Lancet.
[84] D. Esseltine,et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. , 2011, The Lancet. Oncology.
[85] D. Tripathy,et al. Trajectories of pain and analgesics in oncology outpatients with metastatic bone pain. , 2011, The journal of pain : official journal of the American Pain Society.
[86] S. Carrara,et al. Celiac plexus block for pancreatic cancer pain in adults. , 2011, The Cochrane database of systematic reviews.
[87] P. Farquhar-smith. Chemotherapy-induced neuropathic pain , 2011, Current opinion in supportive and palliative care.
[88] J. Paice. Chronic treatment-related pain in cancer survivors , 2011, PAIN.
[89] E. Philip,et al. Psychological distress in patients with pancreatic cancer—an understudied group , 2010, Psycho-oncology.
[90] G. Cavaletti,et al. Chemotherapy-induced peripheral neurotoxicity , 2010, Nature Reviews Neurology.
[91] A. Jakubowiak,et al. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies , 2010, Leukemia & lymphoma.
[92] J. Farrar,et al. Assessment of cancer-related neuropathy and neuropathic pain. , 2010, The oncologist.
[93] K. Anderson,et al. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[94] A. Sahgal,et al. Retrospective assessment of cancer pain management in an outpatient palliative radiotherapy clinic using the Pain Management Index. , 2010, Journal of pain and symptom management.
[95] G. Cavaletti,et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. , 2010, European journal of cancer.
[96] Jeff Myers,et al. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting , 2010, Supportive Care in Cancer.
[97] K. Nemoto,et al. Time Course of Pain Relief in Patients Treated With Radiotherapy for Cancer Pain: A Prospective Study , 2010, The Clinical journal of pain.
[98] R. Koul,et al. Bone Metastasis – an overview , 2009 .
[99] J. Cuzick,et al. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] F. De Conno,et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[101] J. Ioannidis,et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, BMJ : British Medical Journal.
[102] Z. Lidar,et al. Surgical management of metastatic bone disease. , 2009, The Journal of bone and joint surgery. American volume.
[103] M. Fallon,et al. Translational medicine: cancer pain mechanisms and management. , 2008, British journal of anaesthesia.
[104] G. La Torre,et al. Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features. , 2008, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[105] Susan Halabi,et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[106] M. Malawer,et al. Metastatic carcinoma of the long bones. , 2007, American family physician.
[107] A. Caraceni,et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale , 2007, Journal of the peripheral nervous system : JPNS.
[108] T. Guise,et al. Cancer-associated bone disease , 2007, Current osteoporosis reports.
[109] B. Davis,et al. Pain in chronic pancreatitis and pancreatic cancer. , 2007, Gastroenterology clinics of North America.
[110] P. Dougherty,et al. Quantitative sensory findings in patients with bortezomib-induced pain. , 2007, The journal of pain : official journal of the American Pain Society.
[111] A. Dickenson,et al. Central neuronal mechanisms in cancer-induced bone pain , 2007, Current opinion in supportive and palliative care.
[112] J. Gralow,et al. Managing metastatic bone pain: the role of bisphosphonates. , 2007, Journal of pain and symptom management.
[113] E. Chow,et al. Symptom clusters in cancer patients with bone metastases , 2007, Supportive Care in Cancer.
[114] P. Ghezzi,et al. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. , 2007, European journal of cancer.
[115] P. Dougherty,et al. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. , 2007, Journal of pain and symptom management.
[116] N. Pouratian,et al. Part II: spinal-cord neoplasms--primary tumours of the bony spine and adjacent soft tissues. , 2007, The Lancet. Oncology.
[117] R. Coleman. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.
[118] G. Hruby,et al. Mild, moderate, or severe pain categorized by patients with cancer with bone metastases. , 2006, Journal of palliative medicine.
[119] G. Dranitsaris,et al. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. , 2006, The oncologist.
[120] F. Lieberman,et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. , 2006, Seminars in oncology.
[121] Linqiu Zhou,et al. Pharmacologic Management of Cancer Pain , 2005, The Journal of the American Osteopathic Association.
[122] S. Paul,et al. Predictors of quality of life in oncology outpatients with pain from bone metastasis. , 2005, Journal of pain and symptom management.
[123] M. Stillman,et al. Chemotherapy-induced peripheral neuropathy. , 2005, Oncology nursing forum.
[124] M. Lam,et al. 186Re-HEDP for metastatic bone pain in breast cancer patients , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[125] Alison P. Klein,et al. Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds , 2004, Cancer Research.
[126] R. Wong,et al. Quality of life after local external beam radiation therapy for symptomatic bone metastases: a prospective evaluation. , 2004, Supportive cancer therapy.
[127] S. Mercadante,et al. Celiac plexus block for pancreatic cancer pain: factors influencing pain, symptoms and quality of life. , 2003, Journal of pain and symptom management.
[128] C. Herndon. Pharmacologic Management of Cancer Pain , 2003, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[129] A. Lissoni,et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale , 2003, Neurology.
[130] E. Cheng. Prospective quality of life research in bony metastatic disease. , 2003, Clinical orthopaedics and related research.
[131] Bagi Cm. Skeletal implications of prostate cancer. , 2003 .
[132] H. Satoh,et al. BONE METASTASIS AS THE FIRST MANIFESTATION OF LUNG CANCER , 2003, International journal of clinical practice.
[133] A. Caraceni,et al. Classification of cancer pain syndromes. , 2001, Oncology.
[134] A. Caraceni. Evaluation and assessment of cancer pain and cancer pain treatment , 2001, Acta anaesthesiologica Scandinavica.
[135] R. Coleman. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.
[136] R. Cook,et al. Methodology for treatment evaluation in patients with cancer metastatic to bone. , 2001, Journal of the National Cancer Institute.
[137] J. Cameron,et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[138] A. Aboulafia,et al. Incidence, location, and diagnostic evaluation of metastatic bone disease. , 2000, The Orthopedic clinics of North America.
[139] J. Rykowski,et al. Efficacy of Neurolytic Celiac Plexus Block in Varying Locations of Pancreatic Cancer: Influence on Pain Relief , 2000, Anesthesiology.
[140] A. Caraceni,et al. An international survey of cancer pain characteristics and syndromes , 1999, PAIN.
[141] K. Lillemoe,et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer , 1999, British Journal of Cancer.
[142] J. Bucholtz. Metastatic epidural spinal cord compression. , 1999, Seminars in oncology nursing.
[143] H. Libshitz,et al. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. , 1998, Journal of pain and symptom management.
[144] Brant Jm. Cancer-related neuropathic pain. , 1998, Nurse practitioner forum.
[145] S. Yoneda,et al. [Bone metastasis of primary lung cancer]. , 1998, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.
[146] Lisa L. Phillips. Managing the pain of bone metastases in the home environment , 1998, The American journal of hospice & palliative care.
[147] A. Caraceni,et al. Pain management in patients with pancreatic carcinoma , 1996, Cancer.
[148] D. Walsh,et al. Symptoms of pancreatic cancer. , 1991, Journal of pain and symptom management.
[149] R. Portenoy,et al. Breakthrough pain: definition, prevalence and characteristics , 1990, Pain.
[150] T. Powles,et al. Assessment of response of bone metastases to systemic treatment in patients with breast cancer , 1983, Cancer.
[151] J. Schmidt,et al. Bone pain in metastatic cancer of prostate. , 1979, Urology.
[152] Victor Barley,et al. Treatment of Cancer , 1908, Nature.
[153] A. Jemal,et al. Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[154] C. Woolf,et al. Towards a mechanism-based approach to pain diagnosis , 2016 .
[155] S. Flatters. The contribution of mitochondria to sensory processing and pain. , 2015, Progress in molecular biology and translational science.
[156] T. Postma,et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[157] B. Laird,et al. A characterization study of breakthrough pain in cancer-induced bone pain , 2012 .
[158] 黒坂 眞二. EORTC QLQ-BM22 and QLQ-C30 quality-of-life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy , 2012 .
[159] R. Pignataro,et al. Chemotherapy Induced Peripheral Neuropathy: Risk Factors, Pathophysiology, Assessment, and Potential Physical Therapy Interventions , 2010 .
[160] K. Wilson,et al. Prevalence and correlates of pain in the Canadian National Palliative Care Survey. , 2009, Pain research & management.
[161] M. Tsao,et al. Has pain management in cancer patients with bone metastases improved? A seven-year review at an outpatient palliative radiotherapy clinic. , 2009, Journal of pain and symptom management.
[162] Wolfgang Schima,et al. Pancreatic adenocarcinoma , 2006, European Radiology.
[163] Matthew P. Goetz,et al. Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem , 2005, Skeletal Radiology.
[164] C. Bagi. Skeletal implications of prostate cancer. , 2003, Journal of musculoskeletal & neuronal interactions.
[165] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.